During the last session, ATAI Life Sciences N.V (NASDAQ:ATAI)’s traded shares were 10.96 million, with the beta value of the company hitting 1.18. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday loss of -10.98% or -$0.28. The 52-week high for the ATAI share is $2.85, that puts it down -25.55 from that peak though still a striking 54.63% gain since the share price plummeted to a 52-week low of $1.03. The company’s market capitalization is $380.91M, and the average trade volume was 2.35 million shares over the past three months.
ATAI Life Sciences N.V (ATAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATAI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
ATAI Life Sciences N.V (ATAI) registered a -10.98% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -10.98% in intraday trading to $2.27, hitting a weekly high. The stock’s 5-day price performance is 7.08%, and it has moved by 70.68% in 30 days. Based on these gigs, the overall price performance for the year is 20.74%.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 62.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, ATAI is trading at a discount of -164.32% off the target high and -164.32% off the low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
In the rating firms’ projections, revenue will increase 159.03% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 250k as predicted by 6 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 44.19%. While earnings are projected to return -217.14% in 2025.
ATAI Dividends
ATAI Life Sciences N.V is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 2.72 million shares, is of MORGAN STANLEY’s that is approximately 1.7111% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.62 million.
